FDA Brief

Warning letters Drugs

FDA warning letter to

Aspen Aesthetics dba Fifty 410

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.

What happened

FDA reviewed the website https://www.fifty410.com in December 2025 and found it offered compounded semaglutide and tirzepatide products. FDA said the pictured labels showed 'Fifty 410' in a way that suggested Fifty 410 was the compounder, though it is not. FDA also said the claim 'clinically proven ingredients' falsely implied FDA approval or evaluation for safety and effectiveness.

What FDA found

  1. FDA said the website's pictured labels identified 'Fifty 410' as if it were the compounder, but it is not.

    FDCA §502(a) [21 U.S.C. §352(a)] and §502(bb) [21 U.S.C. §352(bb)]; 21 CFR §201.1(h)(2)
  2. FDA said the claim 'clinically proven ingredients' implies FDA approval or safety and effectiveness review that compounded drugs have not received.

    FDCA §502(a) [21 U.S.C. §352(a)] and §502(bb) [21 U.S.C. §352(bb)]
  3. FDA said these misbranded drugs were introduced or delivered for introduction into interstate commerce.

    FDCA §301(a) [21 U.S.C. §331(a)]
  4. FDA also noted that receiving misbranded drugs in interstate commerce, or delivering them, is prohibited.

    FDCA §301(c) [21 U.S.C. §331(c)]

What FDA wants

Within 15 working days, respond in writing to CDER's Office of Compounding Quality and Compliance with steps taken to correct the violations and prevent recurrence. Include the entities that produce the products, sample labeling, and how the website claims were addressed or removed.

Who should pay attention

  • telehealth companies selling compounded GLP-1 drugs
  • compounding pharmacies whose products are marketed by telehealth sites
  • marketers making 'clinically proven' claims for compounded drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low